These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 21940714)

  • 1. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
    Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
    J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
    Yu V; Fisch T; Long AM; Tang J; Lee JH; Hierl M; Chen H; Yakowec P; Schwandner R; Emkey R
    J Biomol Screen; 2012 Jan; 17(1):27-38. PubMed ID: 21859682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based assays to support the profiling of small molecules with histone methyltransferase and demethylase modulatory activity.
    Martinez NJ; Simeonov A
    Drug Discov Today Technol; 2015 Nov; 18():9-17. PubMed ID: 26723887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
    Eglen RM; Reisine T
    J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
    Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
    ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for lysine-specific demethylase-1 inhibitors using a label-free high-throughput mass spectrometry assay.
    Plant M; Dineen T; Cheng A; Long AM; Chen H; Morgenstern KA
    Anal Biochem; 2011 Dec; 419(2):217-27. PubMed ID: 21855527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting histone lysine methylation in cancer.
    McGrath J; Trojer P
    Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient hit-finding approaches for histone methyltransferases: the key parameters.
    Ahrens T; Bergner A; Sheppard D; Hafenbradl D
    J Biomol Screen; 2012 Jan; 17(1):85-98. PubMed ID: 21990582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncoepigenomics: making histone lysine methylation count.
    Decarlo D; Hadden MK
    Eur J Med Chem; 2012 Oct; 56():179-94. PubMed ID: 22975593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TR-FRET cellular assays for interrogating posttranslational modifications of histone H3.
    Machleidt T; Robers MB; Hermanson SB; Dudek JM; Bi K
    J Biomol Screen; 2011 Dec; 16(10):1236-46. PubMed ID: 21972037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell-based high-throughput screening assay to measure cellular histone h3 lys27 trimethylation with a modified dissociation-enhanced lanthanide fluorescent immunoassay.
    Xie W; Ames RS; Li H
    J Biomol Screen; 2012 Jan; 17(1):99-107. PubMed ID: 22086723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening assays for epigenetic targets using native histones as substrates.
    Hauser AT; Bissinger EM; Metzger E; Repenning A; Bauer UM; Mai A; Schüle R; Jung M
    J Biomol Screen; 2012 Jan; 17(1):18-26. PubMed ID: 21965113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.
    Shi Y; Lan F; Matson C; Mulligan P; Whetstine JR; Cole PA; Casero RA; Shi Y
    Cell; 2004 Dec; 119(7):941-53. PubMed ID: 15620353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cell-active lysine specific demethylase 1-selective inhibitors.
    Ueda R; Suzuki T; Mino K; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Am Chem Soc; 2009 Dec; 131(48):17536-7. PubMed ID: 19950987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate.
    Schmitt ML; Ladwein KI; Carlino L; Schulz-Fincke J; Willmann D; Metzger E; Schilcher P; Imhof A; Schüle R; Sippl W; Jung M
    J Biomol Screen; 2014 Jul; 19(6):973-8. PubMed ID: 24687155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and function of histone H3 lysine 9 methyltransferases and demethylases.
    Krishnan S; Horowitz S; Trievel RC
    Chembiochem; 2011 Jan; 12(2):254-63. PubMed ID: 21243713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.